Literature DB >> 11288878

Experimental proof for the structure of a thrombin-inhibiting heparin molecule.

M Petitou1, A Imberty, P Duchaussoy, P A Driguez, M L Ceccato, F Gourvenec, P Sizun, J P Hérault, S Pérez, J M Herbert.   

Abstract

Kinetic studies of thrombin inhibition by antithrombin in the presence of heparin have shown that thrombin binds to heparin in a preformed heparin-antithrombin complex. To study the relative position of the thrombin binding domain and the antithrombin binding domain on a heparin molecule we have designed and synthesized heparin mimetics, which structurally are very similar to the genuine polysaccharide. Their inhibitory properties with respect to factor Xa and thrombin provide experimental evidence that in heparin the thrombin binding domain must be located at the nonreducing end of the antithrombin binding domain to observe thrombin inhibition. As expected, factor Xa inhibition is not affected by elongation of the antithrombin binding pentasaccharide sequence, regardless of the position in which this elongation takes place.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11288878     DOI: 10.1002/1521-3765(20010216)7:4<858::aid-chem858>3.0.co;2-n

Source DB:  PubMed          Journal:  Chemistry        ISSN: 0947-6539            Impact factor:   5.236


  7 in total

Review 1.  Oral direct thrombin inhibition: an effective and novel approach for venous thromboembolism.

Authors:  Sylvia Haas
Journal:  Drugs       Date:  2004       Impact factor: 9.546

2.  Modular synthesis of heparan sulfate oligosaccharides for structure-activity relationship studies.

Authors:  Sailaja Arungundram; Kanar Al-Mafraji; Jinkeng Asong; Franklin E Leach; I Jonathan Amster; Andre Venot; Jeremy E Turnbull; Geert-Jan Boons
Journal:  J Am Chem Soc       Date:  2009-12-02       Impact factor: 15.419

3.  M118, a novel low-molecular weight heparin with decreased polydispersity leads to enhanced anticoagulant activity and thrombotic occlusion in ApoE knockout mice.

Authors:  Subrata Chakrabarti; Lea M Beaulieu; Lara A Reyelt; Mark D Iafrati; Jane E Freedman
Journal:  J Thromb Thrombolysis       Date:  2009-11       Impact factor: 2.300

4.  Rational design of low-molecular weight heparins with improved in vivo activity.

Authors:  Mallik Sundaram; Yiwei Qi; Zachary Shriver; Dongfang Liu; Ganlin Zhao; Ganesh Venkataraman; Robert Langer; Ram Sasisekharan
Journal:  Proc Natl Acad Sci U S A       Date:  2003-01-13       Impact factor: 11.205

5.  More than a biomarker: the systemic consequences of heparan sulfate fragments released during endothelial surface layer degradation (2017 Grover Conference Series).

Authors:  Kaori Oshima; Sarah M Haeger; Joseph A Hippensteel; Paco S Herson; Eric P Schmidt
Journal:  Pulm Circ       Date:  2018 Jan-Mar       Impact factor: 3.017

6.  Synthesis of Streptococcus pneumoniae serotype 9V oligosaccharide antigens.

Authors:  Sharavathi G Parameswarappa; Claney L Pereira; Peter H Seeberger
Journal:  Beilstein J Org Chem       Date:  2020-07-15       Impact factor: 2.883

7.  New Insights in Thrombin Inhibition Structure-Activity Relationships by Characterization of Octadecasaccharides from Low Molecular Weight Heparin.

Authors:  Pierre A J Mourier; Olivier Y Guichard; Fréderic Herman; Philippe Sizun; Christian Viskov
Journal:  Molecules       Date:  2017-03-08       Impact factor: 4.411

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.